Max Meyrath

Latest publications

CXCL14 Preferentially Synergizes With Homeostatic Chemokine Receptor Systems.

  • Immuno-Pharmacology and Interactomics
October 05, 2020
2020 Oct. Front Immunol.11:561404.
By:
  • Kouzeli A
  • Collins PJ
  • Metzemaekers M
  • Meyrath M
  • Szpakowska M
  • Artinger M
  • Struyf S
  • Proost P
  • Chevigne A
  • Legler DF
  • Eberl M
  • Moser B.

The atypical chemokine receptor ACKR3/CXCR7 is a broad-spectrum scavenger for opioid peptides.

  • Immuno-Pharmacology and Interactomics
  • Immune Endocrine and Epigenetics
  • Transversal Translational Medicine
  • Allergy and Clinical Immunology
June 19, 2020
2020 Jun. Nat Commun.11(1):3033.
By:
  • Meyrath M
  • Szpakowska M
  • Zeiner J
  • Massotte L
  • Merz MP
  • Benkel T
  • Simon K
  • Ohnmacht J
  • Turner JD
  • Kruger R
  • Seutin V
  • Ollert M
  • Kostenis E
  • Chevigne A.

Systematic reassessment of chemokine-receptor pairings confirms CCL20 but not CXCL13 and extends the spectrum of ACKR4 agonists to CCL22.

  • Immuno-Pharmacology and Interactomics
June 01, 2020
2020 Jun. J Leukoc Biol. Online ahead of print.
By:
  • Meyrath M
  • Reynders N
  • Uchanski T
  • Chevigne A
  • Szpakowska M.

Assessment of biased agonism among distinct synthetic cannabinoid receptor agonist scaffolds.

  • Immuno-Pharmacology and Interactomics
April 10, 2020
2020 Apr. ACS Pharmacol Transl Sci.3(2):285-295.
By:
  • Wouters E
  • Walraed J
  • Robertson MJ
  • Meyrath M
  • Szpakowska M
  • Chevigne A
  • Skiniotis G
  • Stove C.

The diverse and complex roles of atypical chemokine receptors in cancer: From molecular biology to clinical relevance and therapy.

  • Immuno-Pharmacology and Interactomics
February 14, 2020
2020 Feb. Adv Cancer Res.145:99-138. Epub 2020 Feb 14.
By:
  • Sjoberg E
  • Meyrath M
  • Chevigne A
  • Ostman A
  • Augsten M
  • Szpakowska M.

The soluble form of pan-RTK inhibitor and tumor suppressor LRIG1 mediates downregulation of AXL through direct protein-protein interaction in glioblastoma.

  • NORLUX Neuro-Oncology Laboratory
  • Multiomics Data Science
  • Immuno-Pharmacology and Interactomics
September 06, 2019
2019 Sep. Neurooncol Adv.1(1):vdz024.
By:
  • Neirinckx V
  • Hau AC
  • Schuster A
  • Fritah S
  • Tiemann K
  • Klein E
  • Nazarov PV
  • Matagne A
  • Szpakowska M
  • Meyrath M
  • Chevigne A
  • Schmidt MHH
  • Niclou SP.

A novel ACKR2-dependent role of fibroblast-derived CXCL14 in epithelial-to-mesenchymal transition and metastasis of breast cancer.

  • Immuno-Pharmacology and Interactomics
June 15, 2019
2019 Jun. Clin Cancer Res.25(12):3702-3717. Epub 2019 Mar 8.
By:
  • Sjoberg E
  • Meyrath M
  • Milde L
  • Herrera M
  • Lovrot J
  • Hagerstrand D
  • Frings O
  • Bartish M
  • Rolny C
  • Sonnhammer E
  • Chevigne A
  • Augsten M
  • Ostman A.

Mutational analysis of the extracellular disulphide bridges of the atypical chemokine receptor ACKR3/CXCR7 uncovers multiple binding and activation modes for its chemokine and endogenous non-chemokine agonists.

  • Immuno-Pharmacology and Interactomics
July 01, 2018
2018 Jul. Biochem Pharmacol.153:299-309. Epub 2018 Mar 9.
By:
  • Szpakowska M
  • Meyrath M
  • Reynders N
  • Counson M
  • Hanson J
  • Steyaert J
  • Chevigne A.

Different contributions of chemokine N-terminal features attest to a different ligand binding mode and a bias towards activation of ACKR3/CXCR7 compared with CXCR4 and CXCR3.

  • Immuno-Pharmacology and Interactomics
May 01, 2018
2018 May. Br J Pharmacol.175(9):1419-1438. Epub 2018 Mar 23.
By:
  • Szpakowska M
  • Nevins AM
  • Meyrath M
  • Rhainds D
  • D'Huys T
  • Guite-Vinet F
  • Dupuis N
  • Gauthier PA
  • Counson M
  • Kleist A
  • St-Onge G
  • Hanson J
  • Schols D
  • Volkman BF
  • Heveker N
  • Chevigne A.